NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04542824 2026-03-03
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT03697512 2026-01-15
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT07247383 2025-11-25
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT01479842 2025-10-15
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02180711 2025-10-15
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
Phase 1/2 Active not recruiting
NCT04447716 2025-09-15
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Thomas Jefferson University
Phase 1 Active not recruiting
NCT04212013 2025-07-23
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT04416451 2025-07-02
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting